Volume 97 Number 4_Suppl
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



Monitoring retention of people living with HIV (PLHIV) in the HIV care and treatment cascade is essential to guide program strategy and evaluate progress toward globally-endorsed 90–90–90 targets (i.e., 90% of PLHIV diagnosed, 81% on sustained antiretroviral therapy (ART), and 73% virally suppressed). We describe national retention from diagnosis throughout the cascade for patients receiving HIV services in Haiti during 1985–2015, with a focus on those receiving HIV services during 2008–2015. Among the 266,256 newly diagnosed PLHIV during 1985–2015, 49% were linked-to-care, 30% started ART, and 18% were retained on ART by the time of database closure. Similarly, among the 192,187 newly diagnosed HIV-positive patients during 2008–2015, 50% were linked to care, 31% started ART, and 19% were retained on ART by the time of database closure. Most patients (90–92%) at all cascade steps were adults (≥ 15 years old), among whom the majority (60–61%) were female. During 2008–2015, outcomes varied significantly across 42 administrative districts (arrondissements) of residence; cumulative linkage-to-care ranged from 23% to 69%, cumulative ART initiation among care enrollees ranged from 2% to 80%, and cumulative ART retention among ART enrollees ranged from 30% to 88%. Compared with adults, children had lower cumulative incidence of ART initiation among care enrollees (64% versus 47%) and lower cumulative retention among ART enrollees (64% versus 50%). Cumulative linkage-to-care was low and should be prioritized for improvement. Variations in outcomes by arrondissement and between adults and children require further investigation and programmatic response.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Article metrics loading...

Loading full text...

Full text loading...



  1. UNAIDS, 2017. AIDSinfo. Available at: http://aidsinfo.unaids.org/. Accessed June 13, 2017.
  2. UNDP, 2015. Human Development Index. Available at: http://hdr.undp.org/en/content/human-development-index-hdi. Accessed September 5, 2016.
  3. WHO, 2016. Global Health Repository Data. Available at: http://apps.who.int/gho/data/node.main.A1444. Accessed September 5, 2016.
  4. Farmer P, ., 2001. Community-based approaches to HIV treatment in resource-poor settings. Lancet 358: 404409.[Crossref]
  5. Severe P, ., 2005. Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med 353: 23252334.[Crossref]
  6. Pierre S, Jannat-Khah D, Fitzgerald DW, Pape J, McNairy ML, , 2016. 10-year survival of patients with AIDS receiving antiretroviral therapy in Haiti. N Engl J Med 374: 397398.[Crossref]
  7. GlobalSecurity, 2017. Haiti Politics. Available at: http://www.globalsecurity.org/military/world/haiti/politics.htm. Accessed September 26, 2016.
  8. Walldorf JA, Joseph P, Valles JS, Sabatier JF, Marston BJ, Jean-Charles K, Louissant E, Tappero JW, , 2012. Recovery of HIV service provision post-earthquake. AIDS 26: 14311436.[Crossref]
  9. Delcher C, Puttkammer N, Arnoux R, Francois K, Griswold M, Zaidi I, Patrice Joseph YA, Marston BJ, , 2016. Validating procedures used to identify duplicate reports in Haiti’s national HIV/AIDS case surveillance system. J Registry Manag 43: 1015.
  10. Koenig SP, Bernard D, Devieux JG, Atwood S, McNairy ML, Severe P, Marcelin A, Julma P, Apollon A, Pape JW, , 2016. Trends in CD4 count testing, retention in pre-ART care, and ART initiation rates over the first decade of expansion of HIV services in Haiti. PLoS One 11: e0146903.[Crossref]
  11. George E, ., 2007. Antiretroviral therapy for HIV-1-infected children in Haiti. J Infect Dis 195: 14111418.[Crossref]
  12. Leger P, Charles M, Severe P, Riviere C, Pape JW, Fitzgerald DW, , 2009. 5-year survival of patients with AIDS receiving antiretroviral therapy in Haiti. N Engl J Med 361: 828829.[Crossref]
  13. UNAIDS, 2014. 90–90–90: An Ambitious Treatment Target to Help End the AIDS Epidemic. Available at: http://www.unaids.org/sites/default/files/media_asset/90-90-90_en_0.pdf. Accessed April 10, 2016.
  14. Rouzier V, ., 2014. Factors impacting the provision of antiretroviral therapy to people living with HIV: the view from Haiti. Antivir Ther 19 (Suppl 3): 91104.[Crossref]
  15. WHO, 2007. Guidance on Provider-Initiated HIV Testing and Counselling in Health Facilities. Available at: http://apps.who.int/iris/bitstream/10665/43688/1/9789241595568_eng.pdf. Accessed August 23, 2016.
  16. Ministry of Health, Haiti, 2013. Manuel de Normes de Prise en Charge Clinique et Therapeutique des Adultes et Adolescents Vivant avec le VIH. Available at: http://www.hivpolicywatch.org/duremaps/data/guidelines/HaitiAdultARTguidelines2013.pdf. Accessed September 5, 2016.
  17. Ministry of Health, Haiti, 2013. Directoves Nationales Pour les Soins et le Traitement des Nourrissons, des Enfants et des Adolescents Exposes au VIH ou Porteurs du Virus. Available at: http://www.hivpolicywatch.org/duremaps/data/guidelines/HaitiPaediatricARTguidelines2013.pdf. Accessed September 1, 2016.
  18. Ministry of Health, Haiti, 2013. Manuel de Normes de Prise en Charge: Clinique et Therapeutique des Adultes et Adolescents Vivant Avec le VIH/SIDA. Available at: http://www.hivpolicywatch.org/duremaps/data/guidelines/HaitiAdultARTguidelines2013.pdf. Accessed September 5, 2016.
  19. WHO, 2015. Guideline on When to Start Antiretroviral Therapy and on Pre-Exposure Prophylaxis for HIV. Available at: http://www.who.int/hiv/pub/guidelines/earlyrelease-arv/en/. Accessed October 19, 2016.
  20. WHO, 2013. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. Available at: http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf. Accessed February 17, 2016.
  21. Matheson AI, Baseman JG, Wagner SH, O’Malley GE, Puttkammer NH, Emmanuel E, Zamor G, Frederic R, Coq NR, Lober WB, , 2012. Implementation and expansion of an electronic medical record for HIV care and treatment in Haiti: an assessment of system use and the impact of large-scale disruptions. Int J Med Inform 81: 244256.[Crossref]
  22. Auld AF, Shiraishi RW, Couto A, Mbofana F, Colborn K, Alfredo C, Ellerbrock TV, Xavier C, Jobarteh K, , 2016. A decade of antiretroviral therapy scale-up in Mozambique: evaluation of outcome trends and new models of service delivery among more than 300,000 patients enrolled during 2004–2013. J Acquir Immune Defic Syndr 73: e11e22.[Crossref]
  23. Rosen S, Fox MP, , 2011. Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med 8: e1001056.[Crossref]
  24. Institute for Health Metrics and Evaluation, 2014. Financing Global Health 2015: Development Assistance Steady on the Path to New Global Goals. Available at: http://www.healthdata.org/policy-report/financing-global-health-2015-development-assistance-steady-path-new-global-goals. Accessed June 10, 2017.
  25. Cohen MS, ., 2011. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365: 493505.[Crossref]
  26. Tanser F, Barnighausen T, Grapsa E, Zaidi J, Newell ML, , 2013. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science 339: 966971.[Crossref]
  27. PEPFAR, 2016. 12th Report to Congress on PEPFAR. Available at: http://www.pepfar.gov/press/c19573.htm. Accessed August 25, 2016.
  28. Heaton LM, Bouey PD, Fu J, Stover J, Fowler TB, Lyerla R, Mahy M, , 2015. Estimating the impact of the US President’s Emergency Plan for AIDS Relief on HIV treatment and prevention programmes in Africa. Sex Transm Infect 91: 615620.[Crossref]
  29. DesRoches R, Comerio M, Eberhard M, Mooney W, Rix GJ, , 2010. Overview of the 2010 Haiti Earthquake. Available at: http://escweb.wr.usgs.gov/share/mooney/142.pdf. Accessed September 29, 2016.
  30. Puttkammer NH, ., 2014. Before and after the earthquake: a case study of attrition from the HIV antiretroviral therapy program in Haiti. Glob Health Action 7: 24572.[Crossref]
  31. Domercant JW, Guillaume FD, Marston BJ, Lowrance DW, Centers for Disease Control and Prevention, , 2015. Update on progress in selected public health programs after the 2010 earthquake and cholera epidemic—Haiti, 2014. MMWR Morb Mortal Wkly Rep 64: 137140.
  32. Vertefeuille JF, Dowell SF, Domercant JW, Tappero JW, , 2013. Cautious optimism on public health in post-earthquake Haiti. Lancet 381: 517519.[Crossref]
  33. Koenig SP, , 2016. Superior Outcomes with Same-Day HIV Testing and ART Initiation. Available at: http://www.natap.org/2016/IAC/IAC_96.htm. Accessed August 30, 2016.
  34. MacKellar DA, ., 2016. Enrollment in HIV care two years after HIV diagnosis in the Kingdom of Swaziland: an evaluation of a national program of new linkage procedures. PLoS One 11: e0150086.[Crossref]
  35. McNairy ML, Lamb MR, Abrams EJ, Elul B, Sahabo R, Hawken MP, Mussa A, Zwede A, Justman J, El-Sadr WM, Identifying Optimal Models of HIV Care and Treatment in Sub-Saharan Africa Study, , 2015. Use of a comprehensive HIV care cascade for evaluating HIV program performance: findings from 4 sub-Saharan African countries. J Acquir Immune Defic Syndr 70: e44e51.[Crossref]
  36. Losina E, ., 2010. The “ART” of linkage: pre-treatment loss to care after HIV diagnosis at two PEPFAR sites in Durban, South Africa. PLoS One 5: e9538.[Crossref]
  37. Rachlis B, Naanyu V, Wachira J, Genberg B, Koech B, Kamene R, Akinyi J, Braitstein P, , 2016. Identifying common barriers and facilitators to linkage and retention in chronic disease care in western Kenya. BMC Public Health 16: 741.[Crossref]
  38. MacPherson P, MacPherson EE, Mwale D, Bertel Squire S, Makombe SD, Corbett EL, Lalloo DG, Desmond N, , 2012. Barriers and facilitators to linkage to ART in primary care: a qualitative study of patients and providers in Blantyre, Malawi. J Int AIDS Soc 15: 18020.
  39. WorldBank. LAC Equity Lab: Country at a Glance. Available at: http://www.worldbank.org/en/topic/poverty/lac-equity-lab1/glance. Accessed June 12, 2017.
  40. Fox MP, Rosen S, Geldsetzer P, Barnighausen T, Negussie E, Beanland R, , 2016. Interventions to improve the rate or timing of initiation of antiretroviral therapy for HIV in sub-Saharan Africa: meta-analyses of effectiveness. J Int AIDS Soc 19: 20888.[Crossref]
  41. Rosen S, ., 2016. Initiating antiretroviral therapy for HIV at a patient’s first clinic visit: the RapIT randomized controlled trial. PLoS Med 13: e1002015.[Crossref]
  42. Farahani M, ., 2016. Variation in attrition at subnational level: review of the Botswana national HIV/AIDS treatment (Masa) programme data (2002–2013). Trop Med Int Health 21: 1827.[Crossref]
  43. Auld AF, ., 2016. Wide variations in compliance with tuberculosis screening guidelines and tuberculosis incidence between antiretroviral therapy facilities—Cote d’Ivoire. PLoS One 11: e0157059.[Crossref]
  44. Skarbinski J, Rosenberg E, Paz-Bailey G, Hall HI, Rose CE, Viall AH, Fagan JL, Lansky A, Mermin JH, , 2015. Human immunodeficiency virus transmission at each step of the care continuum in the United States. JAMA Intern Med 175: 588596.[Crossref]
  45. Hoffman S, LSTART Team and the Identifying Optimal Models of HIV Care Collaboration., , 2014. Advanced disease at enrollment in HIV care in four sub-Saharan African countries: change from 2006 to 2011 and multilevel predictors in 2011. AIDS 28: 24292438.[Crossref]
  46. Siedner MJ, Ng CK, Bassett IV, Katz IT, Bangsberg DR, Tsai AC, , 2015. Trends in CD4 count at presentation to care and treatment initiation in sub-Saharan Africa, 2002–2013: a meta-analysis. Clin Infect Dis 60: 11201127.
  47. Rosen S, Fox MP, Larson BA, Sow PS, Ehrenkranz PD, Venter F, Manabe YC, Kaplan J, Models for Accelerating Treatment Initiation (MATI) Technical Consultation, , 2016. Accelerating the uptake and timing of antiretroviral therapy initiation in sub-Saharan Africa: an operations research agenda. PLoS Med 13: e1002106.[Crossref]
  48. Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F, , 2004. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet 364: 12361243.[Crossref]
  49. Auld AF, ., 2014. Antiretroviral therapy enrollment characteristics and outcomes among HIV-infected adolescents and young adults compared with older adults—seven African countries, 2004–2013. MMWR Morb Mortal Wkly Rep 63: 10971103.
  50. Idele P, Gillespie A, Porth T, Suzuki C, Mahy M, Kasedde S, Luo C, , 2014. Epidemiology of HIV and AIDS among adolescents: current status, inequities, and data gaps. J Acquir Immune Defic Syndr 66 (Suppl 2): S144S153.[Crossref]
  51. Kasedde S, Luo C, McClure C, Chandan U, , 2013. Reducing HIV and AIDS in adolescents: opportunities and challenges. Curr HIV/AIDS Rep 10: 159168.[Crossref]
  52. Brinkhof MW, Pujades-Rodriguez M, Egger M, , 2009. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS One 4: e5790.[Crossref]
  53. Geng EH, ., 2015. Estimation of mortality among HIV-infected people on antiretroviral treatment in east Africa: a sampling based approach in an observational, multisite, cohort study. Lancet HIV 2: e107e116.[Crossref]
  54. Cornell M, Lessells R, Fox MP, Garone DB, Giddy J, Fenner L, Myer L, Boulle A, IeDEA-Southern Africa Collaboration, , 2014. Mortality among adults transferred and lost to follow-up from antiretroviral therapy programmes in South Africa: a multicenter cohort study. J Acquir Immune Defic Syndr 67: e67e75.[Crossref]
  55. Bamford A, PENTA Steering Committee., , 2015. Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life. HIV Med, doi:10.1111/hiv.12217.
  56. Prendergast AJ, Penazzato M, Cotton M, Musoke P, Mulenga V, Abrams EJ, Gibb DM, , 2012. Treatment of young children with HIV infection: using evidence to inform policymakers. PLoS Med 9: e1001273.[Crossref]
  57. Geng EH, Bangsberg DR, Musinguzi N, Emenyonu N, Bwana MB, Yiannoutsos CT, Glidden DV, Deeks SG, Martin JN, , 2010. Understanding reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a sampling-based approach. J Acquir Immune Defic Syndr 53: 405411.[Crossref]
  58. Lambdin BH, Micek MA, Koepsell TD, Hughes JP, Sherr K, Pfeiffer J, Karagianis M, Lara J, Gloyd SS, Stergachis A, , 2011. Patient volume, human resource levels, and attrition from HIV treatment programs in central Mozambique. J Acquir Immune Defic Syndr 57: e33e39.[Crossref]
  59. Wouters E, Heunis C, van Rensburg D, Meulemans H, , 2008. Patient satisfaction with antiretroviral services at primary health-care facilities in the Free State, South Africa—a two-year study using four waves of cross-sectional data. BMC Health Serv Res 8: 210.[Crossref]
  60. Gupta RK, Lucas SB, Fielding KL, Lawn SD, , 2015. Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settings: a systematic review and meta-analysis. AIDS 29: 19872002.[Crossref]
  61. Danel C, TEMPRANO ANRS 12136 Study Group., , 2015. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med 373: 808822.[Crossref]
  62. Harries AD, Zachariah R, Lawn SD, Rosen S, , 2010. Strategies to improve patient retention on antiretroviral therapy in sub-Saharan Africa. Trop Med Int Health 15 (Suppl 1): 7075.[Crossref]
  63. UNAIDS, 2013. Global Report: UNAIDS Report on the Global AIDS Epidemic. Available at: http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_en.pdf. Accessed February 17, 2016.
  64. PEPFAR. Haiti Country Operational Plan (COP/ROP) 2016: Strategic Direction Summary. Available at: http://www.pepfar.gov/documents/organization/257647.pdf. Accessed September 29, 2016.
  65. PEPFAR. PEPFAR 3.0: Controlling the Epidemic: Delivering on the Promise of an AIDS-Free Generation. Available at: www.PEPFAR.gov. Accessed September 3, 2016.
  66. Auld AF, Mbofana F, Shiraishi RW, Alfredo C, Sanchez M, Ellerbrock TV, Nelson LJ, , 2013. Incidence and determinants of tuberculosis among adults initiating antiretroviral therapy—Mozambique, 2004–2008. PLoS One 8: e54665.[Crossref]
  67. Geng EH, Emenyonu N, Bwana MB, Glidden DV, Martin JN, , 2008. Sampling-based approach to determining outcomes of patients lost to follow-up in antiretroviral therapy scale-up programs in Africa. JAMA 300: 506507.[Crossref]
  68. Egger M, IeDEA East Africa, West Africa and Southern Africa., , 2011. Correcting mortality for loss to follow-up: a nomogram applied to antiretroviral treatment programmes in sub-Saharan Africa. PLoS Med 8: e1000390.[Crossref]

Data & Media loading...

  • Received : 15 Feb 2017
  • Accepted : 24 Jun 2017

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error